Avani Dave, OD
Corneal and Contact Management · Buffalo, NYNPI 1285157966
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $97,302 of the $121,760 with a category attached, or 79.9%. Bausch & Lomb Americas Inc. accounts for 82.5% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $77,832, more than ten times the $359 reported in 2019. Among corneal and contact management clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $509.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$100K
- Tarsus Pharmaceuticals, Inc.$18K
- AbbVie$1K
- Alcon$404
- Kala Pharmaceuticals, Inc.$246
- Johnson & Johnson Vision Care, Inc.$208
- plus $1K from 9 others
What the payments were for
- Consulting fees$1,4251%
- Speaking & faculty fees$97,30280%
- Travel & lodging$15,74213%
- Food & beverage$7,2736%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 169 | $100,416 |
| Tarsus Pharmaceuticals, Inc. | 28 | $17,996 |
| AbbVie(2 entities) | 7 | $1,366 |
| Alcon | 13 | $404 |
| Kala Pharmaceuticals, Inc. | 2 | $246 |
| Johnson & Johnson Vision Care, Inc. | 3 | $208 |
| Sight Sciences, Inc. | 2 | $199 |
| Sun Pharmaceutical Industries Inc. | 5 | $186 |
| Coopervision Inc. | 2 | $174 |
| Oyster Point Pharma, Inc. | 1 | $125 |
| Amgen | 1 | $125 |
| Thea Pharma Inc. | 1 | $120 |
| Rxsight Inc | 2 | $107 |
| Harrow Eye, LLC | 2 | $73 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$78,752
- XIIDRA$78,627
- ZENLENS$16,295
- XDEMVY$12,001
- VUITY$975
- BLINK NUTRITEARS$500
- EYSUVIS$372
- ALDEN SCLERAL ZENLENS$127
- LUMIGAN$125
- COMBIGAN$125
- RESTASIS MULTIDOSE$125
- TYRVAYA$125
- TEPEZZA$125
- VYZULTA$125
- INVELTYS$122
- IYUZEH$120
- OMNI$119
- Onefit Contact Lens$118
- RESTASIS$115
- Acuvue$100
How this compares
$121,760 in reported general payments places this provider in the 95th percentile of 68 corneal and contact management providers in New York.
See all corneal and contact management providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 120 | $175,314 |
| RestasisCyclosporine | 143 | $163,928 |
| MieboPerfluorohexyloctane/Pf | 199 | $157,947 |
| Cyclosporine | 140 | $71,333 |
| CequaCyclosporine | 51 | $60,428 |
| XdemvyLotilaner | 21 | $36,694 |
| LumiganBimatoprost | 66 | $35,700 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $13,167 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $10,022 |
| VyzultaLatanoprostene Bunod | 21 | $9,368 |
| EysuvisLoteprednol Etabonate | 16 | $7,815 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,959 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $5,630 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 41 | $3,186 |
| Brimonidine Tartrate | 73 | $2,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $100,416 | $342,629340 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,366 | $209,650233 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $186 | $60,42851 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $17,996 | $36,69421 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $246 | $7,81516 claims |
| AlconSimbrinza | $404 | $5,95921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 68 corneal and contact management providers in New York.
Other corneal and contact management in Buffalo
- Michele LaganaHoneoye Falls$248K
- Kevin RosinNew York$59K
- Jeffrey CooperBrooklyn$52K
- Kevork NiksarliNew York$27K
- Richard MalaraBaldwinsville$8K
- David BraunSyracuse$7K
- Michael RaffBrockport$6K
- Angela DussanLong Island City$6K
- Christina ChernyNew York$5K
- Nadine EisenbergNew York$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.